From: Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis
 | Health system perspective | Societal perspective |
---|---|---|
Mild (GMFCS level I/II) | 33,524 | 3,581,722 |
Moderate (GMFCS level III) | 70,923 | 4,500,094 |
Severe (GMFCS level IV/V) | 61,378 | 2,208,153 |